Abstract
Aurora kinases are essential for the regulation of chromosome segregation and cytokinesis during mitosis and play a role in tumorigenesis and tumor progression in humans. Aurora kinase A and Aurora kinase B are overexpressed in some gynecologic cancers, and their overexpression is associated with poor prognosis. Thus, targeting of Aurora kinases has become an attractive strategy for pharmaceutical companies, who have developed more than 30 Aurora kinase inhibitors for treatment of cancers. Some of these inhibitors have been shown to be effective in targeted therapies for human cancer, and others are currently being investigated. In this review, we summarize the most recent advances in preclinical studies and clinical trials of patented Aurora kinase inhibitors for gynecologic tumors.
Keywords: Gynecologic malignancies, Aurora kinases, Aurora kinase inhibitors
Recent Patents on Anti-Cancer Drug Discovery
Title: Update on Aurora Kinase Inhibitors in Gynecologic Malignancies
Volume: 3 Issue: 3
Author(s): Xia Tao, Hye S. Chon, Siqing Fu, John J. Kavanagh and Wei Hu
Affiliation:
Keywords: Gynecologic malignancies, Aurora kinases, Aurora kinase inhibitors
Abstract: Aurora kinases are essential for the regulation of chromosome segregation and cytokinesis during mitosis and play a role in tumorigenesis and tumor progression in humans. Aurora kinase A and Aurora kinase B are overexpressed in some gynecologic cancers, and their overexpression is associated with poor prognosis. Thus, targeting of Aurora kinases has become an attractive strategy for pharmaceutical companies, who have developed more than 30 Aurora kinase inhibitors for treatment of cancers. Some of these inhibitors have been shown to be effective in targeted therapies for human cancer, and others are currently being investigated. In this review, we summarize the most recent advances in preclinical studies and clinical trials of patented Aurora kinase inhibitors for gynecologic tumors.
Export Options
About this article
Cite this article as:
Tao Xia, Chon S. Hye, Fu Siqing, Kavanagh J. John and Hu Wei, Update on Aurora Kinase Inhibitors in Gynecologic Malignancies, Recent Patents on Anti-Cancer Drug Discovery 2008; 3 (3) . https://dx.doi.org/10.2174/157489208786242322
DOI https://dx.doi.org/10.2174/157489208786242322 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Emerging Pathophysiological Targets of Psoriasis for Future Therapeutic Strategies
Infectious Disorders - Drug Targets Mechanism of Action of Flavonoids as Anti-inflammatory Agents: A Review
Inflammation & Allergy - Drug Targets (Discontinued) Alpha9Alpha10 Nicotinic Acetylcholine Receptors as Target for the Treatment of Chronic Pain
Current Pharmaceutical Design Pharmacokinetics-Pharmacology Disconnection of Herbal Medicines and its Potential Solutions with Cellular Pharmacokinetic-Pharmacodynamic Strategy
Current Drug Metabolism 8-bromo-7-methoxychrysin Reversed M2 Polarization of Tumor-associated Macrophages Induced by Liver Cancer Stem-like Cells
Anti-Cancer Agents in Medicinal Chemistry Graphical Abstracts
Current Nanoscience The Association of Chemotherapy and Radiotherapy: Biological Rationale
Current Drug Therapy Calcium Antagonists: A Ready Prescription for Treating Infectious Diseases?
Current Topics in Medicinal Chemistry 6-Bromo-2,3-Dioxoindolin Phenylacetamide Derivatives: Synthesis, Potent CDC25B, PTP1B Inhibitors and Anticancer Activity
Letters in Drug Design & Discovery Synthetic Mono/di-halogenated Coumarin Derivatives and Their Anticancer Properties
Anti-Cancer Agents in Medicinal Chemistry Ligand-modified Biopolymeric Nanoparticles as Efficient Tools for Targeted Cancer Therapy
Current Pharmaceutical Design Exploring PLAC1 Structure and Underlying Mechanisms to Design a Derivative Vaccine Against Breast Cancer Progression; <i>In-Silico</i> Study
Current Proteomics Meet Our Associate Editor
Current Molecular Medicine The University of New Mexico Center for Molecular Discovery
Combinatorial Chemistry & High Throughput Screening In Vitro Antioxidant Activity of Some Novel Synthetic Mononuclear Ruthenium (II) Compounds
Letters in Drug Design & Discovery Meditation: A Review of its Use in Western Medicine and, in Particular, its Role in the Management of Sexual Dysfunction
Current Psychiatry Reviews Treatment of Squamous Cell Carcinoma of the Head and Neck in the Metastatic and Refractory Settings: Advances in Chemotherapy and the Emergence of Small Molecule Epidermal Growth Factor Receptor Kinase Inhibitors
Current Cancer Drug Targets B Cell Modulation Strategies in Autoimmunity: The SLE Example
Current Pharmaceutical Design Hair Loss Prevention by a Scalp Cooling Device in Early Breast Cancer Patients: The Poliambulanza Preliminary Experience
Reviews on Recent Clinical Trials Nutritional Modulation of Terminal End Buds: Its Relevance to Breast Cancer Prevention
Current Cancer Drug Targets